Efficacy of Choleretics in Acalculous Gallbladder in Situ After Endoscopic Removal of Biliary Stones
A Prospective Multicenter Comparative Study for Efficacy of Choleretics in Acalculous Gallbladder in Situ After Endoscopic Removal of Biliary Stones
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Tae Hoon Lee, MD, PhD
- Phone Number: +82-41-570-3662
- Email: thlee9@schmc.ac.kr
Study Locations
-
-
Chungcheongnam-do
-
Cheonan, Chungcheongnam-do, Korea, Republic of, 330-721
- Recruiting
- Soon Chun Hyang University Cheonan Hospital
-
Contact:
- Tae Hoon Lee, MD, PhD
-
Principal Investigator:
- Tae Hoon Lee, MD, PhD
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Complete clearance of CBD stones
- No definite GB stones
- Agree with the study protocol
Exclusion Criteria:
- < 18 years of age
- Concomitant IHD stones
- Combined malignancy with a limted life span
- Prior cholecystectomy state
- refusal to agree to the study protocol
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
Wait-and-see group
After endoscopic clearance of their bile duct stones, this group of patients will be follow up without additional managements
|
|
Choleretics group
After endoscopic clearance of their bile duct stones, this group of patients receives choleretic agents during 3 months
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Complications
Time Frame: two year
|
The primary outcome is biliary complications between two groups during follow-up.
|
two year
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Natural outcomes
Time Frame: two year
|
Other outcome measures included adverse events after choleretics and natural clinical courses of gallbladder in situ.
|
two year
|
|
Other adverse events
Time Frame: two year
|
Other outcome measures included adverse events after choleretics and natural outcomes of gallbladder in situ.
|
two year
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Drug-related adverse event
Time Frame: three months
|
Other outcome measure includes adverse events after choleretics.
|
three months
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- SCH-MULTI
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.